A 55-year-old Japanese man was admitted to Oita University Hospital (Oita, Japan) for pyrexia, malaise and dyspnea, and abnormal shadows on chest radiographs.
He had started receiving sunitinib (37.5 mg a day for 3 weeks, followed by a 3-week break before beginning the next dosing cycle) for metastatic renal cell carcinoma after the improvement of temsirolimus-induced interstitial pneumonia. Sunitinib is a multiple tyrosine kinase receptor inhibitor approved for the treatment of metastatic renal cell carcinoma, and the most common clinical adverse effects of sunitinib are diarrhea, mucositis, stomatitis, hypertension, rashes and altered taste. We herein report a rare case of sunitinib-related interstitial pneumonia after treatment with temsirolimus for metastatic renal cell carcinoma. This case suggests the possibility of recall phenomenon of drug-induced pneumonia during the administration of additional chemotherapy.
Written by:
Kushima H, Ishii H, Kadota JI. Are you the author?
Department of Respiratory Medicine and Infectious Diseases, Oita University Hospital, Oita, Japan.
Reference: Int J Urol. 2013 Oct 29. Epub ahead of print.
doi: 10.1111/iju.12332
PubMed Abstract
PMID: 24168290
UroToday.com Renal Cancer Section
